Literature DB >> 22948274

Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification.

P Font1, J Loscertales, C Benavente, A Bermejo, M Callejas, L Garcia-Alonso, A Garcia-Marcilla, S Gil, M Lopez-Rubio, E Martin, C Muñoz, P Ricard, C Soto, P Balsalobre, A Villegas.   

Abstract

Morphology is the basis of the diagnosis of myelodysplastic syndromes (MDS). The WHO classification offers prognostic information and helps with the treatment decisions. However, morphological changes are subject to potential inter-observer variance. The aim of our study was to explore the reliability of the 2008 WHO classification of MDS, reviewing 100 samples previously diagnosed with MDS using the 2001 WHO criteria. Specimens were collected from 10 hospitals and were evaluated by 10 morphologists, working in five pairs. Each observer evaluated 20 samples, and each sample was analyzed independently by two morphologists. The second observer was blinded to the clinical and laboratory data, except for the peripheral blood (PB) counts. Nineteen cases were considered as unclassified MDS (MDS-U) by the 2001 WHO classification, but only three remained as MDS-U by the 2008 WHO proposal. Discordance was observed in 26 of the 95 samples considered suitable (27 %). Although there were a high number of observers taking part, the rate of discordance was quite similar among the five pairs. The inter-observer concordance was very good regarding refractory anemia with excess blasts type 1 (RAEB-1) (10 of 12 cases, 84 %), RAEB-2 (nine of 10 cases, 90 %), and also good regarding refractory cytopenia with multilineage dysplasia (37 of 50 cases, 74 %). However, the categories with unilineage dysplasia were not reproducible in most of the cases. The rate of concordance with refractory cytopenia with unilineage dysplasia was 40 % (two of five cases) and 25 % with RA with ring sideroblasts (two of eight). Our results show that the 2008 WHO classification gives a more accurate stratification of MDS but also illustrates the difficulty in diagnosing MDS with unilineage dysplasia.

Entities:  

Mesh:

Year:  2012        PMID: 22948274     DOI: 10.1007/s00277-012-1565-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  18 in total

1.  Inter-observer agreement in myelodysplastic syndromes.

Authors:  Fernando Ramos; Silvia Fernández-Ferrero
Journal:  Haematologica       Date:  2013-07       Impact factor: 9.941

2.  Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study.

Authors:  Kasiani C Myers; Elissa Furutani; Edie Weller; Bradford Siegele; Ashley Galvin; Valerie Arsenault; Blanche P Alter; Farid Boulad; Carlos Bueso-Ramos; Lauri Burroughs; Paul Castillo; James Connelly; Stella M Davies; Courtney D DiNardo; Iftikhar Hanif; Richard H Ho; Nicole Karras; Michelle Manalang; Lisa J McReynolds; Taizo A Nakano; Grzegorz Nalepa; Maxim Norkin; Matthew J Oberley; Etan Orgel; Yves D Pastore; Joseph Rosenthal; Kelly Walkovich; Jordan Larson; Maggie Malsch; M Tarek Elghetany; Mark D Fleming; Akiko Shimamura
Journal:  Lancet Haematol       Date:  2019-12-23       Impact factor: 18.959

3.  Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.

Authors:  Eric J Duncavage; Geoffrey L Uy; Allegra A Petti; Christopher A Miller; Yi-Shan Lee; Bevan Tandon; Feng Gao; Catrina C Fronick; Michelle O'Laughlin; Robert S Fulton; Richard K Wilson; Meagan A Jacoby; Amanda F Cashen; Lukas D Wartman; Matthew J Walter; Peter Westervelt; Daniel C Link; John F DiPersio; Timothy J Ley; John S Welch
Journal:  Blood       Date:  2017-01-12       Impact factor: 22.113

Review 4.  The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS).

Authors:  David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 5.  Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

Authors:  Aaron C Shaver; Adam C Seegmiller
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

6.  MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.

Authors:  Brian Kwok; Jeff M Hall; John S Witte; Yin Xu; Prashanti Reddy; Keming Lin; Rachel Flamholz; Bashar Dabbas; Aine Yung; Jenan Al-Hafidh; Emily Balmert; Christine Vaupel; Carlos El Hader; Matthew J McGinniss; Shareef A Nahas; Julie Kines; Rafael Bejar
Journal:  Blood       Date:  2015-10-01       Impact factor: 22.113

Review 7.  Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.

Authors:  James A Kennedy; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

8.  The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.

Authors:  Christopher R Cogle; Sandra E Kurtin; Tanya G K Bentley; Michael S Broder; Eunice Chang; Scott Megaffin; Steven Fruchtman; Michael E Petrone; Sudipto Mukherjee
Journal:  Oncologist       Date:  2017-03-10

9.  The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia.

Authors:  Gang Zheng; Ping Chen; Aparna Pallavajjalla; Lisa Haley; Lukasz Gondek; Amy Dezern; Hua Ling; Federico De Marchi; Ming-Tseh Lin; Christopher Gocke
Journal:  Am J Hematol       Date:  2019-08-07       Impact factor: 13.265

10.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.